Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 3

1(12.5%)

Phase 2

1(12.5%)

8Total

Phase 1(6)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03850574Phase 1Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT04477291Phase 1Terminated

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Role: lead

NCT03893682Phase 1Terminated

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Role: lead

NCT02267863Phase 1Terminated

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Role: lead

NCT00565058Phase 2Completed

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

Role: lead

NCT01281592Phase 1Completed

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Role: lead

NCT00040092Phase 3Completed

A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

Role: lead

NCT00056173Phase 1Completed

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Role: lead

All 8 trials loaded